{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Salt+tablet&page=2",
    "query": {
      "intervention": "Salt tablet",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Salt+tablet&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-05T05:31:46.154Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02588352",
      "title": "Evaluation of Salt Sensitivity in Young Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Salt tablet",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "21 Years to 30 Years"
      },
      "enrollment_count": 40,
      "start_date": "2012-05",
      "completion_date": "2015-03",
      "has_results": false,
      "last_update_posted_date": "2016-05-19",
      "last_synced_at": "2026-09-05T05:31:46.154Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02588352"
    },
    {
      "nct_id": "NCT00896389",
      "title": "Salt Loading and Thiazide Intervention Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "Salt loading",
          "type": "PROCEDURE"
        },
        {
          "name": "Hydrochlorothiazide (HCTZ)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 124,
      "start_date": "2009-10",
      "completion_date": "2013-03",
      "has_results": true,
      "last_update_posted_date": "2022-03-25",
      "last_synced_at": "2026-09-05T05:31:46.154Z",
      "location_count": 1,
      "location_summary": "Lancaster, Pennsylvania",
      "locations": [
        {
          "city": "Lancaster",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00896389"
    },
    {
      "nct_id": "NCT00280280",
      "title": "Botox vs. Baclofen for Upper Limb Spasticity",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Spasticity"
      ],
      "interventions": [
        {
          "name": "intramuscular Botox versus oral baclofen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2006-02",
      "completion_date": "2009-02",
      "has_results": false,
      "last_update_posted_date": "2012-01-20",
      "last_synced_at": "2026-09-05T05:31:46.154Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00280280"
    },
    {
      "nct_id": "NCT02422797",
      "title": "Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "DTG 50 mg",
          "type": "DRUG"
        },
        {
          "name": "RPV 25 mg",
          "type": "DRUG"
        },
        {
          "name": "CAR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 518,
      "start_date": "2015-04-21",
      "completion_date": "2023-05-25",
      "has_results": true,
      "last_update_posted_date": "2024-09-03",
      "last_synced_at": "2026-09-05T05:31:46.154Z",
      "location_count": 13,
      "location_summary": "Bakersfield, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 9 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Vero Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02422797"
    },
    {
      "nct_id": "NCT01595516",
      "title": "Nebivolol and Endothelial Regulation of Fibrinolysis (NERF)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Prehypertension",
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "Nebivolol",
          "type": "DRUG"
        },
        {
          "name": "Metoprolol",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Bradykinin",
          "type": "OTHER"
        },
        {
          "name": "Saline",
          "type": "OTHER"
        },
        {
          "name": "Vitamin C",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Colorado, Boulder",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "45 Years to 65 Years"
      },
      "enrollment_count": 44,
      "start_date": "2012-02",
      "completion_date": "2017-10",
      "has_results": true,
      "last_update_posted_date": "2019-06-25",
      "last_synced_at": "2026-09-05T05:31:46.154Z",
      "location_count": 1,
      "location_summary": "Boulder, Colorado",
      "locations": [
        {
          "city": "Boulder",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01595516"
    },
    {
      "nct_id": "NCT01848340",
      "title": "An Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV-associated Lipodystrophy Syndrome"
      ],
      "interventions": [
        {
          "name": "GSK1265744B (sodium salt) containing 14C-GSK1265744B",
          "type": "DRUG"
        },
        {
          "name": "150 mg GSK1265744B",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 16,
      "start_date": "2013-05",
      "completion_date": "2013-07",
      "has_results": false,
      "last_update_posted_date": "2013-11-04",
      "last_synced_at": "2026-09-05T05:31:46.154Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01848340"
    },
    {
      "nct_id": "NCT06983054",
      "title": "DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study, a Randomized, Placebo-controlled, Cross-over Study With Ertugliflozin in People With Type 2 Diabetes",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "ertugliflozine",
          "type": "DRUG"
        },
        {
          "name": "low salt diet",
          "type": "BEHAVIORAL"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "high salt diet",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Amsterdam UMC, location VUmc",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 34,
      "start_date": "2023-07-25",
      "completion_date": "2025-12",
      "has_results": false,
      "last_update_posted_date": "2025-05-21",
      "last_synced_at": "2026-09-05T05:31:46.154Z",
      "location_count": 1,
      "location_summary": "Denver, Colorado",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06983054"
    },
    {
      "nct_id": "NCT01074294",
      "title": "Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Attention Deficit Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "OPDC-34712",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Stimulant Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 740,
      "start_date": "2010-03-16",
      "completion_date": "2011-06-20",
      "has_results": true,
      "last_update_posted_date": "2023-02-02",
      "last_synced_at": "2026-09-05T05:31:46.154Z",
      "location_count": 35,
      "location_summary": "Little Rock, Arkansas • Beverly Hills, California • Irvine, California + 32 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01074294"
    },
    {
      "nct_id": "NCT01235962",
      "title": "A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Renal Cell Carcinoma (RCC)",
        "Cancer"
      ],
      "interventions": [
        {
          "name": "pazopanib",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1538,
      "start_date": "2010-11-30",
      "completion_date": "2019-04-15",
      "has_results": true,
      "last_update_posted_date": "2020-11-23",
      "last_synced_at": "2026-09-05T05:31:46.154Z",
      "location_count": 69,
      "location_summary": "Jonesboro, Arkansas • Antioch, California • Beverly Hills, California + 53 more",
      "locations": [
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Antioch",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01235962"
    },
    {
      "nct_id": "NCT01187901",
      "title": "A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adenomatous Polyposis Coli"
      ],
      "interventions": [
        {
          "name": "Erlotinib",
          "type": "DRUG"
        },
        {
          "name": "Sulindac",
          "type": "DRUG"
        },
        {
          "name": "Placebo A",
          "type": "DRUG"
        },
        {
          "name": "Placebo B",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "18 Years to 69 Years"
      },
      "enrollment_count": 92,
      "start_date": "2010-04",
      "completion_date": "2014-07",
      "has_results": true,
      "last_update_posted_date": "2016-06-17",
      "last_synced_at": "2026-09-05T05:31:46.154Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01187901"
    }
  ]
}